Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
26
CLGN Quote, Financials, Valuation and Earnings
Last price:
$1.49
Seasonality move
:
10.82%
Day range:
$1.42 - $1.50
52-week range:
$1.30 - $4.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.14x
P/B ratio:
2.05x
Volume:
52.6K
Avg. volume:
25.2K
1-year change:
-58%
Market cap:
$19M
Revenue:
$515K
EPS (TTM):
-$1.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CLGN
CollPlant Biotechnologies Ltd.
|
$5M | -- | 1161.42% | -- | $11.56 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $3.25 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | -7.77% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CLGN
CollPlant Biotechnologies Ltd.
|
$1.49 | $11.56 | $19M | -- | $0.00 | 0% | 7.14x |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.18 | $3.25 | $2.8M | -- | $0.00 | 0% | 1.34x |
|
CGEN
Compugen Ltd.
|
$1.54 | $6.25 | $143.6M | 55.83x | $0.00 | 0% | 20.51x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.00 | $399.00 | $3.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CLGN
CollPlant Biotechnologies Ltd.
|
24.01% | 3.313 | 8.55% | 3.36x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CLGN
CollPlant Biotechnologies Ltd.
|
-$415K | -$3.5M | -76.25% | -94.13% | -4554.55% | -$3.2M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
CollPlant Biotechnologies Ltd. vs. Competitors
-
Which has Higher Returns CLGN or CANF?
Can-Fite BioPharma Ltd. has a net margin of -4523.38% compared to CollPlant Biotechnologies Ltd.'s net margin of --. CollPlant Biotechnologies Ltd.'s return on equity of -94.13% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CLGNCollPlant Biotechnologies Ltd.-538.96% -$0.27 $12.2M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About CLGN or CANF?
CollPlant Biotechnologies Ltd. has a consensus price target of $11.56, signalling upside risk potential of 686.4%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $3.25 which suggests that it could grow by 1251.35%. Given that Can-Fite BioPharma Ltd. has higher upside potential than CollPlant Biotechnologies Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than CollPlant Biotechnologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CLGNCollPlant Biotechnologies Ltd.2 0 0 CANFCan-Fite BioPharma Ltd.2 0 0 -
Is CLGN or CANF More Risky?
CollPlant Biotechnologies Ltd. has a beta of 0.672, which suggesting that the stock is 32.834% less volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock CLGN or CANF?
CollPlant Biotechnologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CollPlant Biotechnologies Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLGN or CANF?
CollPlant Biotechnologies Ltd. quarterly revenues are $77K, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. CollPlant Biotechnologies Ltd.'s net income of -$3.5M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, CollPlant Biotechnologies Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CollPlant Biotechnologies Ltd. is 7.14x versus 1.34x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLGNCollPlant Biotechnologies Ltd.7.14x -- $77K -$3.5M CANFCan-Fite BioPharma Ltd.1.34x -- -- --
-
Which has Higher Returns CLGN or CGEN?
Compugen Ltd. has a net margin of -4523.38% compared to CollPlant Biotechnologies Ltd.'s net margin of -369.06%. CollPlant Biotechnologies Ltd.'s return on equity of -94.13% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital CLGNCollPlant Biotechnologies Ltd.-538.96% -$0.27 $12.2M CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About CLGN or CGEN?
CollPlant Biotechnologies Ltd. has a consensus price target of $11.56, signalling upside risk potential of 686.4%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 311.18%. Given that CollPlant Biotechnologies Ltd. has higher upside potential than Compugen Ltd., analysts believe CollPlant Biotechnologies Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CLGNCollPlant Biotechnologies Ltd.2 0 0 CGENCompugen Ltd.4 0 0 -
Is CLGN or CGEN More Risky?
CollPlant Biotechnologies Ltd. has a beta of 0.672, which suggesting that the stock is 32.834% less volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock CLGN or CGEN?
CollPlant Biotechnologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CollPlant Biotechnologies Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLGN or CGEN?
CollPlant Biotechnologies Ltd. quarterly revenues are $77K, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. CollPlant Biotechnologies Ltd.'s net income of -$3.5M is higher than Compugen Ltd.'s net income of -$7M. Notably, CollPlant Biotechnologies Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CollPlant Biotechnologies Ltd. is 7.14x versus 20.51x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLGNCollPlant Biotechnologies Ltd.7.14x -- $77K -$3.5M CGENCompugen Ltd.20.51x 55.83x $1.9M -$7M
-
Which has Higher Returns CLGN or NSRX?
Nasus Pharma has a net margin of -4523.38% compared to CollPlant Biotechnologies Ltd.'s net margin of --. CollPlant Biotechnologies Ltd.'s return on equity of -94.13% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CLGNCollPlant Biotechnologies Ltd.-538.96% -$0.27 $12.2M NSRXNasus Pharma-- -- -- -
What do Analysts Say About CLGN or NSRX?
CollPlant Biotechnologies Ltd. has a consensus price target of $11.56, signalling upside risk potential of 686.4%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that CollPlant Biotechnologies Ltd. has higher upside potential than Nasus Pharma, analysts believe CollPlant Biotechnologies Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings CLGNCollPlant Biotechnologies Ltd.2 0 0 NSRXNasus Pharma0 0 0 -
Is CLGN or NSRX More Risky?
CollPlant Biotechnologies Ltd. has a beta of 0.672, which suggesting that the stock is 32.834% less volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CLGN or NSRX?
CollPlant Biotechnologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CollPlant Biotechnologies Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLGN or NSRX?
CollPlant Biotechnologies Ltd. quarterly revenues are $77K, which are larger than Nasus Pharma quarterly revenues of --. CollPlant Biotechnologies Ltd.'s net income of -$3.5M is higher than Nasus Pharma's net income of --. Notably, CollPlant Biotechnologies Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CollPlant Biotechnologies Ltd. is 7.14x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLGNCollPlant Biotechnologies Ltd.7.14x -- $77K -$3.5M NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns CLGN or PHGE?
BiomX, Inc. has a net margin of -4523.38% compared to CollPlant Biotechnologies Ltd.'s net margin of --. CollPlant Biotechnologies Ltd.'s return on equity of -94.13% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital CLGNCollPlant Biotechnologies Ltd.-538.96% -$0.27 $12.2M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About CLGN or PHGE?
CollPlant Biotechnologies Ltd. has a consensus price target of $11.56, signalling upside risk potential of 686.4%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8150%. Given that BiomX, Inc. has higher upside potential than CollPlant Biotechnologies Ltd., analysts believe BiomX, Inc. is more attractive than CollPlant Biotechnologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CLGNCollPlant Biotechnologies Ltd.2 0 0 PHGEBiomX, Inc.1 0 0 -
Is CLGN or PHGE More Risky?
CollPlant Biotechnologies Ltd. has a beta of 0.672, which suggesting that the stock is 32.834% less volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock CLGN or PHGE?
CollPlant Biotechnologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CollPlant Biotechnologies Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLGN or PHGE?
CollPlant Biotechnologies Ltd. quarterly revenues are $77K, which are larger than BiomX, Inc. quarterly revenues of --. CollPlant Biotechnologies Ltd.'s net income of -$3.5M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, CollPlant Biotechnologies Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CollPlant Biotechnologies Ltd. is 7.14x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLGNCollPlant Biotechnologies Ltd.7.14x -- $77K -$3.5M PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
